Treatment histories of borderline inpatients☆
Abstract
In this study, we describe the types and amounts of psychiatric treatment received by a well-defined sample of borderline personality disorder (BPD) inpatients, and compare these parameters with those of a group of carefully diagnosed personality-disordered controls. Finally, we assess the risk factors associated with a history of intensive, high-cost treatment, which we defined as having had two or more prior psychiatric hospitalizations. The treatment histories of 290 borderline inpatients and 72 axis II controls were assessed using a reliable semistructured interview. All nine forms of treatment studied except electroconvulsive therapy (ECT) were common among borderline patients (36% to 96%). In addition, a significantly higher percentage of borderline patients than axis II controls reported a history of individual and group therapy, day and residential treatment, psychiatric hospitalization, participating in self-help groups, and taking standing medications. They were also significantly younger when they first entered individual therapy and began to take standing medications. In addition, borderline patients spent more time than axis II controls in individual therapy and psychiatric hospitals, and were on standing medications for a significantly longer period of time. They also reported a significantly higher number of psychiatric hospitalizations, lifetime number of standing medications, and number of psychotropic medications taken at the same time. In addition, we found a highly significant multivariate predictive model for multiple prior hospitalizations. The six significant predictors were age 26 or older, a history of quasi psychotic thought, lifetime number of self-mutilative efforts and suicide attempts, a childhood history of reported sexual abuse, and an adult history of being physically and/or sexually assaulted. Taken together, these results confirm clinical impressions concerning the high rates of mental health services used by borderline patients. They also suggest that particularly high rates of costly inpatient treatment are associated with a complex admixture of older age, BPD symptoms in the cognitive and impulse realms, and traumatic life experiences occurring in both childhood and adulthood.
References (0)
Cited by (244)
Repetitive negative thoughts and thought control strategies within borderline personality disorder: A systematic review
2024, Journal of Affective Disorders ReportsRecent research has acknowledged the role of cognitive processes, such as repetitive negative thinking, in the development and maintenance of BPD symptoms. The identification of cognitive processes contributing to BPD symptoms can significantly improve the treatment and conceptualization of this disorder. Despite the promising clinical utility in treating cognitive processes underlying BPD symptoms, there continues to be a lack of research examining the role of specific types of repetitive negative thoughts within BPD. The purpose of this review is to summarize previous research related to repetitive negative thoughts and strategies for coping with negative thoughts in relation to BPD to advance research in cognitive dysregulation. A literature review consistent with PRISMA guidelines was conducted to identify peer-reviewed research on repetitive negative thoughts, thought control strategies, and borderline personality disorder. Articles (N = 69) were summarized and included within the review. While recent research has identified repetitive negative thoughts as contributing to the presence of emotional and behavioral dysregulation within BPD, additional research is needed to examine how various types of thinking styles and ways of controlling thoughts interact with emotional and behavioral components of BPD.
The roles of borderline personality disorder symptoms and dispositional capability for suicide in suicidal ideation and suicide attempts: Examination of the COMT Val158Met polymorphism
2021, Psychiatry ResearchThere is a need to identify the subset of individuals with borderline personality disorder (BPD) symptoms at greatest risk for transitioning from suicidal ideation to a suicide attempt. Contemporary models of suicide risk propose that the capability for suicide is necessary for moving from suicidal ideation to a suicide attempt. Few studies have examined dispositional capability factors for suicide, especially among individuals with BPD symptoms. One candidate may be the catechol-o-methyltransferase (COMT) Val158Met polymorphism given its influence on pain sensitivity and fear. This study examined the interactive relation of BPD symptoms and the COMT Val158Met polymorphism to suicidal ideation and suicide attempts. Fifty-nine treatment-seeking patients were recruited. Participants were administered a series of clinical interviews to evaluate BPD symptoms and suicidal thoughts and behaviors. Saliva samples were collected for genotyping. The relation between BPD symptoms and suicidal ideation was not influenced by the Val158Met polymorphism. However, among Val/Val carriers, the probability of a lifetime suicide attempt increased as BPD symptom severity increased. Findings provide preliminary support for the Val/Val variant as a dispositional factor that may increase risk for suicide attempts in BPD; however, results must be interpreted with caution until replication of findings occurs in larger samples.
Psychopharmacological treatment in borderline personality disorder: A pilot observational study in a real-world setting
2021, Psychiatry ResearchPsychotherapy is the cornerstone of treatment for borderline personality disorder (BPD) while pharmacotherapy should be considered only as an adjunctive intervention. In clinical practice, however, most of BPD patients only receive medication. The aim of the study is to first describe pharmacological treatment in BPD patients in Italy and secondly to evaluate if comorbidity or illness severity are associated with the prescription of different class compounds.
Data on pharmacological treatment and clinical evaluation of 75 BPD patients were collected in 5 clinical settings. The association between comorbidity and medication was assessed. Moreover, we evaluated the association between pharmacotherapy and severity, defined by a cluster analysis aimed at detecting different groups of patients.
Most of the participants (82.7%) were characterized by polypharmacy, with a mean of 2.4 medications per person. Interestingly, the prescription didn't seem to depend on/be based on the severity of the disorder and was only partially determined by the presence of comorbidity.
In conclusion, our findings are similar to what described in other clinical studies, supporting the idea that medication management for BPD is only partially coherent with international guidelines. This pilot study confirms the need for more rigorous studies to gain greater understanding of this topic and diminish the gap between guidelines and the real clinical world.
Change in core symptoms of borderline personality disorder by tDCS: A pilot study
2020, Psychiatry ResearchBorderline personality disorder (BPD) recognizes several psychopathological dimensions related to prefrontal cortex impairments. Transcranial Direct Current Stimulation (tDCS) targeting the right prefrontal dorsolateral cortex (DLPFC) positively influence cognitive functions related to impulsivity in healthy subjects. A randomized double-blind study was designed to investigate whether tDCS could modulate core dimensions (impulsivity, aggression, affective dysregulation) of BPD. Also effects on decision making process and substances craving was assessed. Patients were randomized to receive active-tDCS at 2 mA versus sham-tDCS, once a day for 15 sessions. Anode was placed on the right DLPFC (F4), cathode on the left DLPFC (F3). Impulsivity and aggression measures were significantly reduced only in patients treated with active-tDCS. Decision-making process was marginally influenced by the active current. Craving intensity was reduced only in the active-tDCS sample. Both groups showed improvements in the affective dysregulation dimension and anxious and depressive symptoms. The application of bilateral tDCS targeting right DLPFC with anodal stimulation seems to improve core dimensions of BPD (mainly impulsivity and aggression) probably by restoring prefrontal activity. tDCS might be a potential tool for preventing self-harming behaviors.
A hierarchical analysis of the latent trait of borderline personality disorder and its possible clinical implications
2020, Psychiatry ResearchBorderline personality disorder (BPD) is a severe mental disorder which is accompanied by impaired functioning, complex psychosocial problems and incurs large costs. However, it rarely has been examined whether BPD symptoms form a hierarchical (Mokken) scale, which would imply that symptoms are ordered along a latent dimension of borderline severity. In this study the data from 1,198 inpatients of a psychosomatic clinic were examined. A non-parametric Mokken analysis was employed to investigate if the BPD symptoms measured by the impulsivity and emotion dysregulation scale (IES-27) formed a hierarchical scale. 16 of the 27 items, mainly regarding emotion dysregulation, formed a monotonous Mokken scale with a very strong hierarchy of BPD symptoms. These results imply that single BPD symptoms provide information about BPD severity, suggesting several important consequences regarding escalation of BPD, diagnosis and treatment, e.g. how to optimize treatment planning.
Validating the biosocial model of borderline personality disorder: Findings from a longitudinal study
2023, Development and Psychopathology
- ☆
Supported in part by National Institute of Mental Health Grant No. MH47588.